Context Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 6.31 million compared to USD 3.44 million a year ago. Basic loss per share from continuing operations was USD 0.4 compared to USD 0.22 a year ago.
Context Therapeutics Inc.
Equities
US21077P1084
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |